Zevra Therapeutics (ZVRA) Finished Goods (2023 - 2024)

Zevra Therapeutics (ZVRA) reported Finished Goods of $1.1 million for Q3 2024, down 45.35% quarter-over-quarter from $2.1 million in Q2 2024.

Zevra Therapeutics (ZVRA) Finished Goods (2023 - 2024) Analysis & Trends

Zevra Therapeutics has reported Finished Goods for 2 years, with the latest figure at $1.1 million in Q3 2024.

For the quarter ending Q3 2024, Finished Goods changed N/A year-over-year to $1.1 million; the trailing twelve-month figure through Sep 2024 stood at $1.1 million (changed N/A YoY), and the FY2023 full-year result was $5.0 million, changed N/A from the prior year.
Finished Goods for Q3 2024 stood at $1.1 million, down from $2.1 million in the prior quarter.
The five-year high for Finished Goods was $5.1 million in Q1 2024, with the low at $1.1 million in Q3 2024.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Alterity Therapeutics	788,338.31 Bn	788,338.28 Bn	-
2	Belite Bio	56,560.00 Bn	56,560.00 Bn	-
3	Quantum Biopharma	17,329.30 Bn	17,329.30 Bn	-
4	Legend Biotech	3,341.00 Bn	3,340.71 Bn	242.10 Mn
5	Akari Therapeutics	1,727.91 Bn	1,727.91 Bn	-
6	Evaxion A	1,536.68 Bn	1,536.67 Bn	-
7	Psyence Biomedical	238.34 Bn	238.33 Bn	-
8	Vertex Pharmaceuticals	113.42 Bn	106.17 Bn	2.59 Bn
9	Abivax	95.45 Bn	95.45 Bn	-
10	Zevra Therapeutics	796.95 Mn	596.33 Mn	34.30 Mn

Download Data